Haemonetics Corporation has announced that for the first time, patients have been treated with the company's VASCADE MVP®? Venous Vascular Closure system in Germany. This marks the first use of the VASCADE system portfolio, widely used in U.S. hospitals, in a European country.

The VASCADE system is designed for "small-bore" femoral arterial and venous closure, generally used in interventional cardiology and peripheral vascular procedures. The VASCADE MVP system is designed for "mid-bore" multi-access femoral venous closure, generally used In electrophysiology procedures. Both closure devices are CE marked under the EU-MDR (European Medical Device Regulations) for use in patients who have undergone catheters with single or multiple access sites in one or both limbs and include proprietary collagen disc technology and a resorbable collagen patch to achieve hemostasis.

The VASCADE and VASCADE MVP systems are designed to save time for hospital staff, while helping patients reach hemostasis faster with fewer complications on average compared to manual compression. Haemonetics is planning further expansion for the VASCADE system portfolio in other markets outside the U.S. Following the German launch, the VASCADE systems have now been released for use in Italy. Haemonetics recently announced the distribution of the VASCADE MVP system in Japan via an exclusive agreement with Japan Lifeline Co.

Ltd. The product is expected to launch in Japan later this year.